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Myelodysplastic syndromes with single neutropenia or
thrombocytopenia are rarely refractory cytopenias with
unilineage dysplasia by World Health Organization 2008
criteria and have favourable prognosis
The World Health Organization 2008 (WHO 2008) classifica-
tion of myelodysplastic syndrome (MDS) individualized a new
‘refractory cytopenia with unilineage dysplasia’ (RCUD) cate-
gory (Brunning et al, 2008) in which two subcategories were
added to the previous refractory anaemia (RA) classification
(WHO 2001; Brunning et al, 2001; Jaffe, 2002), i.e. refractory
neutropenia (RN) and refractory thrombocytopenia (RT),
defined by dysplasia in only one myeloid lineage, and one or
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two cytopenias. However, very few reports have addressed the
frequency and clinical relevance of RN and RT, and whether
these WHO diagnoses apply to patients with a single blood
cytopenia, particularly thrombocytopenia or neutropenia.
Among 1910 MDS patients included in its registry before
2010, the Groupe Francophone des Myelodysplasies (GFM)
identified 29 cases of isolated neutropenia (IN; absolute neu-
trophil count <15 9 109/l) and 38 of isolated thrombocy-
Table I. Patient characteristics.
IA IN IT All
N (%) 1142 (79) 134 (9) 169 (12) 1445 (100)
Sex
Female 572 (50) 58 (43) 67 (40) 697 (48)
Male 570 (50) 76 (57) 102 (60) 748 (52)
Age
Median (range) 76 (17–99) 684 (30–87) 702 (26–92) 741 (17–99)
Blood count, median (range)
Haemoglobin, g/l 89 (30–119) 130 (120–159) 132 (120–186) 91 (30–186)
MCV, fL
ANC, 9 109/l 34 (15–28) 089 (01–149) 29 (15–32) 3 (01–32)
Platelet count, 109/l 267 (100–1540) 179 (100–419) 65 (2–99) 232 (2–1540)
Country
France 266 (23) 77 (57) 87 (51) 430 (30)
Germany 523 (46) 4 (3) 8 (5) 535 (37)
Italy 353 (31) 53 (40) 74 (44) 480 (33)
WHO 2001 diagnosis*
RA 253 (22) 22 (16) 26 (15) 301 (21)
RARS 233 (20) 0 (0) 2 (1) 235 (16)
RCMD 273 (24) 32 (24) 62 (37) 367 (25)
RCMD-RS 87 (8) 2 (1) (0) 89 (6)
5q- 71 (6) 3 (2) 4 (2) 78 (5)
RAEB-1 125 (11) 26 (19) 33 (20) 184 (13)
RAEB-2 65 (6) 29 (22) 11 (7) 105 (7)
MDS-U 16 (1) 16 (12) 29 (17) 61 (4)
AML/sAML 19 (1) 4 (2) 2 (1) 25 (1)
WHO 2008 diagnosis*
N (%) 523 (88) 29 (5) 42 (7) 594 (100)
RA 54 (10) – – 54 (9)
RN – 2 (7) – 2 (0)
RT – – 1 (2) 1 (0)
ICUS – – 2 (5) 2 (0)
RARS 107 (20) 1 (2) 108 (18)
RCMD 255 (49) 11 (38) 20 (48) 286 (48)
5q- 39 (7) 1 (3) 1 (2) 41 (7)
RAEB-1 35 (7) 10 (34) 12 (29) 57 (10)
RAEB-2 20 (4) 5 (17) 5 (12) 30 (5)
AML 13 (2) – – 13 (2)
IPSS category
Low/int-1 967 (85) 79 (59) 130 (77) 1176 (81)
Int-2-High 81 (7) 33 (25) 14 (8) 128 (9)
Unknown 94 (8) 22 (16) 25 (15) 141 (10)
5q-, 5q- syndrome; AML, acute myeloid leukaemia; ANC, absolute neutrophil count; IA, isolated anaemia; ICUS, isolated cytopenia of unknown
significance; IN, isolated neutropenia; Int-1/Int-2, intermediate 1/2; IPSS, international prognostic scoring system; IT, isolated thrombocytopenia;
MCV, mean corpuscular volume; MDS-U, myelodysplastic syndrome, unclassifiable; RA, refractory anaemia; RAEB, refractory anaemia with
excess blasts; RARS, refractory anaemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory
cytopenia with multilineage dysplasia and ringed sideroblasts; RN, refractory neutropenia; RT, refractory thrombocytopenia; sAML, secondary
AML; WHO, World Health Organization.
*The WHO 2001 cohort corresponds to the patients diagnosed since the beginning of the registries, who were all classified according to the
WHO 2001 classification. The WHO 2008 cohort is the subgroup of patients of the WHO 2001 cohort who have been diagnosed after 2008, and
for which the WHO 2008 diagnosis was available.
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topenia (IT; platelet count <100 9 109/l), with monocytes
<1 9 109/l. After a review based on WHO 2008 criteria, the
main diagnosis was refractory cytopenia with multilineage
dysplasia (RCMD; 373%), followed by refractory anaemia
with excess blasts, type 1 (RAEB-1; 343%) and RAEB-2
(119%), while only 3 patients were classified as RCUD (2
RN and 1 RT). An additional cytopenia developed in 204%
of IN and 402% of IT within 3 years (P = 012).
To confirm the rare occurrence of WHO 2008 RN and RT
diagnoses, a cooperative study between the GFM, German
(D€usseldorf) and Italian Fondazione Italiana per le Sindromi
Mielodisplastiche (FISM) MDS registries was conducted, ana-
lysing patients with isolated anaemia (IA, defined by haemo-
globin level <120 g/l) in addition to those with IN and IT.
The three multicentre registries prospectively collected the
same minimal data set from records of consenting MDS
patients after obtaining Institutional Review Board/ethics
committee approval in each individual centre.
Among the patients included in the 3 registries at 1 May
2012, 1445 MDS with a single cytopenia were identified
(79% IA, 9% IN, 12% IT; Table I). Median age was 76, 684
and 702 years in the IA, IN and IT groups, respectively
(P < 0001, ANOVA test).
The most frequent WHO 2001 diagnosis in the whole
1445 group and in the 3 IA, IN and IT subgroups was
RCMD (representing 25%, 24%, 24% and 37% of the
patients, respectively), followed by RA (16% of IA), RAEB-2
(22% of IN) and RAEB-1 (20% of IT). MDS unclassifiable
(MDS-U) was diagnosed in 1% of IA, 12% of IN and 18%
of IT. The International Prognostic Scoring System (IPSS)
category (Greenberg et al, 1997) was Low/Int-1 (81%), Int-2/
High (9%) and undetermined (10%) due to missing or failed
cytogenetics.
In the 594 patients diagnosed with single cytopenia after
2008 and thus also classified by WHO 2008 criteria, the most
frequent diagnosis was still RCMD (48% of all patients, 49%
IA, 38% IN, and 48% IT), followed by refractory anaemia
with ringed sideroblasts (RARS) for IA (20%), and RAEB-1
for both IN (34%) and IT (20%). RA accounted for only
10% of patients with IA, RN for 2 (7%) of 29 IN, and RT
Fig 1. Outcome of patients with an isolated refractory cytopenia (A) Incidence of evolution to acute myeloid leukaemia (AML) in patients with-
out AML at diagnosis. Logrank P = 008. (B) Overall survival. Logrank P < 0001. (C) Overall survival of refractory cytopenia with multilineage
dysplasia (RCMD) patients according to the type and number of cytopenias. Logrank P < 0001. (D) Overall survival of refractory anaemia with
excess blasts (RAEB-1) patients according to the type and number of cytopenias. Logrank P = 0002. (E) Overall survival of refractory cytopenia
with unilineage dysplasia (RCUD) and myelodysplastic syndrome-unclassifiable (MDS-U) according to the nature and number of cytopenias. The
‘no cytopenia’ and ‘2 cytopenias’ groups curves are superimposed. Logrank P = 0004. IA, isolated anaemia (dotted line). IN, isolated neutropenia
(dark grey line). IT, isolated thrombocytopenia (solid line). No cytopenias, light grey line. MDS with 2 or 3 cytopenias, light grey dotted line.
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for 1 (2%) of 42 IT. Additionally, 2 idiopathic cytopenia of
unknown significance were diagnosed in the IT group.
Median follow-up of the whole 1445 patient cohort was
316 months. After exclusion of the 25 patients with acute
myeloid leukaemia (AML) at diagnosis, the probability of
AML evolution at 2 years was 109%, 211% and 146% for
IA, IN, and IT, respectively, with no significant difference
(Log rank P = 008, Fig 1A). Overall survival of the IA group
was significantly shorter than that of the IN and the IT
groups (median 534, 91 and 129 months, respectively
P < 0001, Fig 1B), reflecting the unfavourable prognosis of
isolated anaemia, which was independent of age and IPSS in
multivariate analysis (data not shown).
Results of this large collaborative study show that the most
frequent WHO 2008 diagnoses in patients with IN or IT are
RCMD and RAEB-1, while RCUD is very rare. In a report
from the D€usseldorf group, RN and RT accounted for only 9%
and 6%, respectively, of RCUD cases, with no prognostic dif-
ference between RT, RN and RA (Maassen et al, 2013).
Although generally classified as relatively poor prognosis
RCMD or RAEB-1 subtypes, IN and IT had a low rate of
AML progression (89% at 3 years) and relatively prolonged
survival (822% at 3 years), comparable to the 75% survival
at 3 years previously described for RCUD in the Pavia cohort
(Cazzola, 2011). On the other hand, Verburgh et al (2007)
reported a median survival was 109 months in patients with
a single cytopenia and unilineage marrow dysplasia, whereas
it was poorer in patients with multilineage dysplasia regard-
less of the number of cytopenias.
Overall survival of IN and IT was significantly better than
that of IA, although IA patients did not have a higher rate of
AML progression. This observation confirms the poor prog-
nostic significance of anaemia in lower risk MDS, at least
when red blood cell transfusion is present (Cazzola & Malco-
vati, 2005). By comparison with the whole RCMD group of
the GFM registry, patients with IT or IN and a RCMD diag-
nosis had better survival than those with two or more
cytopenias (P < 0001), and was similar to that of patients
with IA (Fig 1C). The same observation was true for RAEB-1
(P = 0002, Fig 1D). For WHO 2008 RCUD and WHO 2001
MDS-U, IT and IN had a longer survival than IA (P = 0004,
Fig 1E), but patients with 2 cytopenias were too few (n = 5)
for further comparison.
Our study therefore questions the frequency of RCUD, a
category introduced by WHO 2008 classification for patients
with one dysplastic lineage and one or 2 cytopenias, as most
patients with a single cytopenia were classified as RCMD.
The good prognostic value of a single cytopenia is already
taken into account by both the IPSS (Greenberg et al, 1997)
and its revised version (Greenberg et al, 2012) for clinical
decision-making. Further molecular studies of these particu-
lar forms of MDS may help understand their significance.
Altogether, our results show that WHO 2008-defined RN
and RT (and to a lesser extent RA), are rare in MDS patients
with IN, IT and IA, and that MDS patients with a single
cytopenia, especially IN and IT, are mostly classified as RCMD
using WHO 2008 criteria. If confirmed in non-Caucasian
groups, these results would encourage RCUD and RCMD to
be merged together in future WHO classifications.
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